REGN Regeneron Pharmaceuticals Inc.

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Regeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)

Regeneron has sponsored ISEF - the world’s largest high school science and engineering competition, and a program of Society for Science (Society) - since 2019

Each year, over 175,000 students participate in the Society’s affiliated high school science fairs around the world to earn the right to compete in Regeneron ISEF, where 1,600 finalists vie for almost $8 million in awards, prizes and scholarships

Regeneron is also lead sponsor of the Society’s Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition

These programs, along with many other Regeneron-supported and driven STEM programs - including the recently announced Together for CHANGETM initiative and a $5 million investment in Nashville’s STEM ecosystem - are engaging and inspiring the next generation of scientific leaders and innovators

TARRYTOWN, N.Y. and WASHINGTON, D.C., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (Society) today announced that Regeneron is increasing and extending its commitment as the title sponsor of the (ISEF), the world’s largest high school science and engineering competition, with a total investment of approximately $34 million over a five-year period.

Established in 1950, Regeneron ISEF gives the world's best and brightest young scientists a global stage to share their outstanding science, technology, engineering and mathematics (STEM) research and compete for nearly $8 million in awards, prizes and scholarships. Each year, over 175,000 students compete in the Society's 400 affiliated high school science fairs around the world. Top winners earn the right to compete at Regeneron ISEF where nearly 1,600 finalists, half of whom are young female scientists, are judged in 22 different categories. 

The renewed sponsorship builds on Regeneron and the Society's long-standing partnership to advance STEM education, including through Regeneron's $100 million, ten-year commitment to the Regeneron Science Talent Search (STS), the nation’s oldest and most prestigious high school science and mathematics competition. 

These high school science competitions play a pivotal role in directing high school students towards STEM careers. According to a study from the , the more STEM competitions students engage in, the higher their likelihood of expressing interest in STEM-related careers by the end of high school — even when factoring in their prior career interests.

“My life-long commitment to using science to fight back against disease started in high school, and was profoundly shaped by my participation in the very competitions we now sponsor," said George D. Yancopoulos, M.D., Ph.D., co-Founder, co-Chair, President, and Chief Scientific Officer at Regeneron, and a principal inventor of several of the world’s leading medicines. “I see it as our duty to engage and inspire the next generation of young scientists. Our renewed commitment and increased investment in Regeneron ISEF are a testament to our belief in these young visionaries who will push the boundaries of science to help change and improve the world.”

The renewed sponsorship includes a $10 million increase from its previous commitment level, allowing Regeneron and the Society to raise the top ISEF award, the , to $100,000 (up from $75,000), the two second place awards, the , to $75,000 each (up from $50,000 each) and increase all category awards by 20 percent. This increase will take effect during Regeneron ISEF 2025. Since Regeneron assumed title sponsorship in 2019, Regeneron ISEF has welcomed over 5,000 high school students representing 64 countries and distributed a total of nearly $22 million in awards, prizes and scholarships to the top young scientists in the world. Regeneron ISEF competitors join the Society’s international network of 60,000 ISEF alumni, which provides networking opportunities and other support to help alumni grow, collaborate and improve our world.

"For over 70 years, ISEF has inspired young STEM enthusiasts from around the globe. This renewed commitment and award increase not only amplifies the grandeur of this global stage but also echoes our shared vision of creating a brighter, science-driven future," said Maya Ajmera, President and CEO of Society for Science and Executive Publisher of Science News. "Witnessing Regeneron's passionate support over the years has been heartening, and their increased investment will undeniably help us nurture dreams, catalyze innovation and embolden the next generation of STEM talent in the years ahead."

Regeneron is proud to support programs and initiatives focused on fostering the next generation of scientific innovators who can solve society’s greatest challenges. The company directs more than 93 percent of its community investments to supporting STEM education locally, nationally and internationally. The increased and extended commitment to Regeneron ISEF follows two other recent STEM-related announcements by Regeneron, including its founding membership of the initiative, a national health and education equity initiative established by Meharry Medical College, as well as a to bolster Nashville, Tennessee’s STEM ecosystem. In Nashville, Regeneron will support existing STEM programs and adapt new initiatives that have proven successful in its New York high school community, as evidenced by student success in competitions like Regeneron ISEF and Regeneron STS.

About Regeneron 

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in our laboratories. Regeneron’s medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases and rare diseases.

Regeneron believes that operating as a good corporate citizen is crucial to delivering on our mission. We approach corporate responsibility with three goals in mind: to improve the lives of people with serious diseases, to foster a culture of integrity and excellence and to build sustainable communities. Regeneron is proud to be included on the Dow Jones Sustainability World Index and the Civic 50 list of the most “community-minded” companies in the United States. Throughout the year, Regeneron empowers and supports employees to give back through our volunteering, pro-bono and matching gift programs. Our most significant philanthropic commitments are in the area of science education, including the  and .

For additional information about Regeneron, please visit  or follow Regeneron on .

About Society for Science 

Society for Science is a champion for science, dedicated to promoting the understanding and appreciation of science and the vital role it plays in human advancement. Established in 1921, Society for Science is best known for its award-winning journalism through Science News and Science News Explores, its world-class science research competitions for students, including the Regeneron Science Talent Search, the Regeneron International Science and Engineering Fair and the Thermo Fisher Scientific Junior Innovators Challenge, and its outreach and equity programming that seeks to ensure that all students have an opportunity to pursue a career in STEM. A 501(c)(3) membership organization, Society for Science is committed to inform, educate and inspire. Learn more at and follow us on , , and Snapchat (Society4Science).

Media Contacts:

Joseph Brown, Regeneron

386-283-1323

Gayle Kansagor, Society for Science

703-489-1131



EN
13/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Cantor Global Healthcare Conference 2025 at 1:35 p.m. ET on Wednesday, September 3, 20252025 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday, September 4, 2025Morgan Stanley 23rd Annual Global Healthcare Conference at 11:30 a.m. ET on Monday, September 8, 2025Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum at 10:30 a.m. ET on Wednesday, Sep...

 PRESS RELEASE

Regeneron Reports Second Quarter 2025 Financial and Operating Results

Regeneron Reports Second Quarter 2025 Financial and Operating Results Second quarter 2025 revenues increased 4% to $3.68 billion versus second quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 22% to $4.34 billion EYLEA HD® U.S. net sales increased 29% to $393 million; total EYLEA HD and EYLEA® U.S. net sales decreased 25% to $1.15 billion GAAP EPS increased 3% to $12.81; non-GAAP EPS(a) increased 12% to $12.89FDA approved Lynozyfic™ (linvoseltamab) for relapsed or refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU)FDA ...

 PRESS RELEASE

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creati...

Regeneron Announces the 2025 Winners of the Regeneron Prize for Creative Innovation TARRYTOWN, N.Y., July 24, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 13th annual Regeneron Prize for Creative Innovation (the “Regeneron Prize”), which recognizes and rewards outstanding creativity and talent among early-career scientists in biomedical research. Each year, top U.S. research universities nominate their most promising graduate students and postdoctoral fellows for this honor. These nominees are invited to develop and pitch thei...

 PRESS RELEASE

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for ...

Lynozyfic™ (linvoseltamab-gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma TARRYTOWN, N.Y., July 02, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody. Lynozy...

 PRESS RELEASE

Regeneron to Report Second Quarter 2025 Financial and Operating Result...

Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025 TARRYTOWN, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2025 financial and operating results on Friday, August 1, 2025, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch